Content Library
Interviews
NEW!
Interview with Cedrik Britten, CMO, Immatics
NEW!
Introducing Captain T Cell
Felix Lorenz
Whitepapers
NEW!
CELL AND GENE THERAPIES:
THE CATALYST FOR NOVEL COMMERCIAL STRATEGIES
Year/Month in Review
NEW!
2021: January in Review
NEW!
2020: Year in Review
Survey Results
NEW!
CAR-TCR Industry Survey 2020
NEW!
CAR-TCR Digital Week Poll Results
CAR-TCR Summit Survey 2020 - Results
Post-Event Reports
NEW!
2020 ASH Post-Event Report
Reading Lists
NEW!
Christmas Reading List
NEW!
2020 Post-Event Report
Webinars
NEW!
Bringing It All Together – From Early Technology Evaluations to Commercial Approval
There is more than meets the eye with cell therapy manufacturing than just scalability. Listen to our discussion with Lonza, ZIOPHARM, MSKCC and Stanford Center for Cancer Cell Therapy on the lessons learned from early technology evaluations to the commercial approval of immunotherapies.
Magazine
CAR-TCR Magazine
Presentations
Key Takeaways from the 'Strategic Dive' Workshops at CAR-TCR Boston 2019
White Paper: Advancing Next Generation Therapeutics
By Sartorius brands; IncuCyte & intellicyt
How to Generate Optimal-Affinity TCRs for the Clinic?
Elisa Kieback,
CEO,
T-Knife
Development of First Manufacturing Process to Produce CAR-Treg Cells for Clinical Use
Pierre Heimendinger,
VP Pharmaceutical Development,
TxCell
Regenerative Medicines and Cell Therapy Products: Is the NICE Therapy Products: Is the NICE Therapy
Grace Hampson,
Senior Economist
The Office of Health Economics